Amphastar Pharmaceuticals (AMPH) Total Non-Current Liabilities (2014 - 2026)

Amphastar Pharmaceuticals' Total Non-Current Liabilities history runs 13 years deep, the most recent figure standing at $868.8 million for Q1 2026.

• In Q1 2026, Total Non-Current Liabilities changed 0.09% year-over-year to $868.8 million; the TTM figure through Mar 2026 stood at $868.8 million (changed 0.09% YoY), while the FY2025 annual figure was $834.6 million, changed 0.44% from the prior year.
• Total Non-Current Liabilities was $868.8 million for Q1 2026 at Amphastar Pharmaceuticals, up from $834.6 million in the prior quarter.
• In the past five years, Total Non-Current Liabilities ranged from a high of $933.8 million in Q3 2023 to a low of $206.1 million in Q4 2022.
• Historically, Total Non-Current Liabilities has averaged $658.6 million across 5 years, with a median of $830.1 million in 2025.
• The sharpest annual moves came in 2023 and 2024: Total Non-Current Liabilities jumped 350.37% in 2023, then slipped 15.35% in 2024.
• A 5-year view of Total Non-Current Liabilities shows it stood at $206.1 million in 2022, then surged by 312.79% to $850.8 million in 2023, then fell by 1.48% to $838.2 million in 2024, then slipped by 0.44% to $834.6 million in 2025, then advanced by 4.11% to $868.8 million in 2026.
• The last three Total Non-Current Liabilities figures came in at $868.8 million (Q1 2026), $834.6 million (Q4 2025), and $882.5 million (Q3 2025), per Business Quant data.